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Abstract
Background. Patients with glioblastoma (GBM) have a poor prognosis and limited effective treatment options. Bevacizumab
has been approved for treatment of recurrent GBM, but there is questionable survival benefit. Based on preclinical and
early clinical data indicating that CD105 upregulation may represent a mechanism of resistance to bevacizumab, we hypothesized that combining bevacizumab with the anti-CD105 antibody TRC105 may improve efficacy in recurrent GBM.
Methods. Phase I dose-escalation/comparative randomized phase II trial in patients with GBM. During phase I, the
maximum tolerated dose (MTD) of TRC105 in combination with bevacizumab was determined. In phase II, patients
were randomized 1:1 to TRC105 and bevacizumab or bevacizumab monotherapy. Patients received TRC105 (10 mg/
kg) weekly and bevacizumab (10 mg/kg) every 2 weeks. Efficacy, as assessed by progression-free survival (PFS),
was the primary endpoint; safety, quality of life, and correlative outcomes were also evaluated.
Results. In total, 15 patients were enrolled in phase I and 101 in phase II; 52 patients were randomized to TRC105
with bevacizumab and 49 to bevacizumab monotherapy. The MTD was determined to be 10 mg/kg TRC105 weekly
plus bevacizumab 10 mg/kg every 2 weeks. An increased occurrence of grade ≥3 adverse events was seen in
the combination arm, including higher incidences of anemia. Median PFS was similar in both treatment arms:
2.9 months for combination versus 3.2 months for bevacizumab monotherapy (HR = 1.16, 95% CI = 0.75–1.78,
P = .51). Quality of life scores were similar for both treatment arms.
Conclusions. TRC105 in combination with bevacizumab was well tolerated in patients with recurrent GBM, but no
difference in efficacy was observed compared to bevacizumab monotherapy.
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Key Points
• TRC105 given in combination with bevacizumab was well tolerated in patients with
GBM.

Importance of the Study
Based on preclinical and early clinical data with
the combination of TRC105 and bevacizumab in
patients with other solid tumors, we hypothesized that blocking CD105 with the anti-CD105
antibody TRC105 could prevent the development of resistance to bevacizumab. There is an
urgent need for novel treatments for patients
with glioblastoma (GBM) as bevacizumab
monotherapy has only modest efficacy. We
investigated the combination of TRC105 and

Glioblastoma (GBM), the most lethal primary malignant
brain tumor, has a median survival of 16–18 months despite multimodality treatment that includes surgery, radiation therapy, and chemotherapy. There is a pressing need
to develop innovative approaches in the treatment of this
disease.1
GBM is a highly vascularized tumor relying heavily on
angiogenesis.2 A key mediator in cancer angiogenesis
is the angiogenic cytokine vascular endothelial growth
factor (VEGF).3 Inhibition of VEGF signaling has been
shown to inhibit glioma tumor growth in several models.4
Bevacizumab is a recombinant humanized monoclonal
antibody (mAb) that binds and neutralizes VEGF activity.
Bevacizumab was granted accelerated approval by the
United States Food and Drug Administration (FDA) for
treatment of recurrent GBM,5–7 which was subsequently
converted to full approval in 2017. While bevacizumab
has an acceptable safety profile and antiglioma activity
as single agent, the survival benefit is still questionable.
Development of rationally designed bevacizumab-based
combinatorial strategies is needed in order to improve efficacy outcomes.
CD105 (endoglin) is a transforming growth factor β
(TGFβ) binding protein that can be found on the surface
of vascular endothelial cells.8 High expression of CD105
has been detected in tissues undergoing active vascularization, such as tumors.9 Microvessel density (MVD),
as determined by the level of anti-CD105 mAb binding
(CD105-MVD), has been shown to correlate with VEGF expression in GBM; patients with higher CD105-MVD tumors
were reported to have a shorter survival time than patients
with low CD105-MVD tumors.8 This was especially true
when increased CD105-MVD was observed in the area situated 1–3.5 cm from the tumor.10 These outcomes suggest
that CD105 expression has a possible prognostic value in
patients with GBM. Moreover, increased levels of CD105

bevacizumab in patients with GBM. While this
combination was well tolerated, no increased
efficacy with the addition of TRC105 was demonstrated. Correlative analyses indicated that
baseline presence of circulating endothelial
cells may impact progression-free survival after
bevacizumab therapy, which could be of interest
for future research, including the development
of combinatorial strategies that can increase efficacy or prevent bevacizumab resistance.

have been observed following VEGF inhibition11 and this
may represent an escape mechanism for the tumor.
TRC105 is a chimeric anti-CD105 IgG1 antibody, formed
of human Cκ and Cγ1 constant regions and murine Vκ
and VH regions,12 that inhibits angiogenesis and has
the potential to complement other anti-angiogenic therapies. Treatment with TRC105 monotherapy in patients
with advanced tumors was shown to be well tolerated,
with possibly early antitumor activity; 47% of patients
achieved stable disease (SD) or better.13 Additionally, the
adverse events (AEs) associated with TRC105 were distinct from those previously observed with VEGF inhibitors,
indicating that these treatments may be safely combined.13
A phase Ib trial evaluating the combination of TRC105 plus
bevacizumab in patients with advanced solid tumors has
shown a tolerable safety profile, with some preliminary
clinical activity.14 Hence, we hypothesized that combining
these two agents in patients with GBM may improve efficacy outcomes and prevent development of bevacizumab
treatment resistance.
Herein, we present data from North Central Cancer
Treatment Group (NCCTG) N1174, a phase I/II study
investigating treatment with TRC105 plus bevacizumab in
patients with recurrent GBM. The aim of the trial was to determine the maximum tolerated dose (MTD) and evaluate
the safety and efficacy of the combination. NCCTG is now
part of the Alliance for Clinical Trials in Oncology.

Materials and Methods
Patients
Eligible patients were ≥18 years old, had evidence of tumor
progression following radiation or other antitumor therapy,
and had measurable or evaluable disease by gadolinium
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• TRC105 + bevacizumab did not improve outcomes vs bevacizumab alone in patients with
recurrent GBM.
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This was a phase I dose-escalation/comparative randomized phase II trial in patients with GBM (NCT01648348). The
primary objective of the phase I part of the study was to
determine the maximum tolerated dose (MTD) of TRC105
when combined with bevacizumab. In addition, pharmacokinetics (PK) of TRC105 were determined as correlative
research. For the phase II part of the study, primary objectives were to assess overall safety and occurrence of AEs,
and to evaluate the efficacy of the combination versus
bevacizumab monotherapy; progression-free survival
(PFS) was the primary endpoint. Secondary objectives included the evaluation of 6-month PFS, overall survival (OS,
defined as length of time from registration until death due
to any cause), time to treatment failure (TTF, defined as the
time from study registration until documentation of progression, unacceptable toxicity or refusal to continue study
participation), and quality of life in both treatment arms.
Correlative research during the phase II trial included the
investigation of the relationship between circulating biomarkers of vascular response and efficacy.
For phase I, a standard 3 + 3 dose-escalation schedule
was applied for TRC105. The following premedications
were administered 0.5–2 hours prior to administration of
TRC105: acetaminophen (650 mg), dexamethasone (20 mg),
famotidine (20 mg), and cetirizine (10 mg). Dexamethasone

Safety
All AEs were evaluated per National Cancer Institute (NCI)
Common Terminology Criteria for Adverse Events (CTCAE)
v4.0 at baseline and each evaluation. AEs were assessed
for likelihood of being related to the study drug and categorized as definite, probable, possible, unlikely to be related, and unrelated.

Response Assessment
Tumor response was assessed using the Response
Assessment
Neuro-Oncology
(RANO)
criteria.15
Measurable disease was defined as bi-dimensionally
contrast-enhancing lesions with clearly defined margins that had two perpendicular diameters ≥10 mm and
were visible on ≥2 axial slices. Tumors around a cyst or
surgical cavity were considered nonmeasurable unless
a nodular component existed with a diameter ≥10 mm.
Disease was considered nonmeasurable when there
were uni-dimensionally lesions, masses without clearly
defined margins, or lesions with a maximal perpendicular diameter <10 mm. For target lesions, a maximum
of 5 measurable lesions were selected (based on the
longest diameters), recorded, and measured at baseline.
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Study Design

doses were tapered over the treatment cycles if previous
TRC105 infusions were well tolerated. TRC105 was administered intravenously (IV) using an infusion pump over
1–4 hours, with starting dose level set at 6 mg/kg weekly.
Subsequent dose levels were 8 mg/kg and 10 mg/kg weekly.
For all patients, the initial dose in cycle 1 was split over days
8 (3 mg/kg IV) and 11 (the remainder of the dose), and subsequent doses given fully on days 1 and 8 of each 2 week
cycle. Bevacizumab was administered at the approved dose
of 10 mg/kg on day 1 of each 2 week cycle. Three patients
were included for each dose level and if 1 of 3 patients exhibited dose-limiting toxicity (DLT), an additional 3 patients
were included at the same dose level. The MTD was defined
as the highest dose when no more than 1 out of 6 patients
had a DLT.
During phase II, patients were randomized 1:1 to TRC105
and bevacizumab or bevacizumab monotherapy. The
TRC105 dose was 10 mg/kg weekly as determined in phase
I. During cycle 1 the dose was split between days 8 (3 mg/
kg) and 11 (7 mg/kg), and in subsequent cycles, the full dose
was administered on days 1 and 8 of each 2 week cycle.
Maximum administered doses of TRC105 were 850 mg for
women and 1000 mg for men. Bevacizumab was given
every 2 weeks, as a 10 mg/kg IV infusion on day 1 of each
2 week cycle. On the days when both bevacizumab and
TRC105 were administered, bevacizumab was given first,
followed by TRC105 premedications and TRC105.
Dose levels of TRC105 could be reduced when patients
experienced AEs; in cycle 1 the day 11 dose could be reduced from 7 mg/kg to 3.5 mg/kg and in subsequent cycles
doses could be reduced to 8, 6, or 3 mg/kg weekly. When
dose-related toxicities were observed at the lowest of
these doses, TRC105 was discontinued. Bevacizumab could
be omitted for the cycle, delayed, or discontinued based on
bevacizumab-related AEs experienced by patients.

Neuro-Oncology
Advances

magnetic resonance imaging (MRI) or contrast computerized tomography (CT) scan. Additionally, all patients were
required to have an Eastern Cooperative Oncology Group
(ECOG) status of 0–2, a life expectancy ≥12 weeks, and adequate hematologic, hepatic, and renal function. The phase
I component of the study enrolled patients with grade 3
or 4 gliomas, including astrocytoma, oligodendroglioma,
and mixed gliomas, as determined by preregistration central pathology review. Patients were allowed to have received any number of prior chemotherapy regimens and
a last dose of bevacizumab ≥2 weeks prior to registration.
Patients were not eligible for the phase I part if they had experienced any prior hypersensitivity to bevacizumab. For
the phase II part, patients with histological confirmation of
GBM, gliosarcoma, or other grade 4 astrocytoma variants
were eligible. Histologic diagnosis was confirmed by central pathology review. Patients were allowed to have had
≤1 chemotherapy or other nonantiangiogenic regimen at
recurrence and have no prior exposure to bevacizumab.
Patients were not eligible for phase II if they had had any
prior exposure to a VEGF inhibitor.
Patients were ineligible for both study phases if they
had prior hypersensitivity to recombinant antibodies or
triptans, had other active malignancies, or uncontrolled
infection. Additional exclusion criteria included a history
of hypertensive crisis or hypertensive encephalopathy,
history of bleeding diathesis, clinically significant cardiovascular or vascular disease, receipt of any other investigational agents, or prior treatment with TRC105. The study
protocol was approved by the Mayo Clinic Institutional
Review Board and conducted in accordance with the
Declaration of Helsinki. Written informed consent was
obtained from each individual participating in the study.
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Pharmacokinetics
For patients enrolled in the phase I part of the study,
serum samples were collected for PK analysis at pre- and
postdose in cycle 1 days 8 and 11, cycle 2 days 1 and 8,
at the end of the study or upon withdrawal, and 28 days
after end of the study. Pre-dose samples were taken immediately prior to the start of TRC105 infusion, and post-dose
samples were collected within 10 minutes of completion of
the infusion.

Circulating Endothelial Cells
Planned correlative analyses included evaluation of cellular biomarkers of vascular response during the phase II
part of the study. Total circulating endothelial cells (CEC)
and CECs with expression of CD105, the putative target of
TRC105, were determined at various time points. Whole
blood samples were collected in EDTA tubes at baseline,
prior to treatment in cycle 2, on cycle 2 day 3 (± 1 day),
prior to treatment in cycle 3, and prior to treatment every
4 weeks thereafter for up to 5 times. In addition, samples
for CEC analysis were acquired at disease progression,
withdrawal, or study discontinuation. Samples had to be
analyzed within 48 hours of collection for results to be
considered valid. CECs were evaluated as previously described.16,17 Briefly, whole blood samples were lysed to remove red blood cells and then stained in BD Pharmingen
Trucount© tubes for the absolute count calculation of endothelial cells. Endothelial cells were identified by their characteristic low forward/side scatter and CD146+CD3-CD31+
phenotype. Cells were additionally stained using CD105
to evaluate activated endothelial cells. Isotype controls
were used to exclude non-specific staining, and 7-aminoactinomycin D staining to exclude dead cells.

Quality of Life
Quality of life was assessed with the EORTC Quality of Life
QLQ-C15-PAL and QLQ-BN20 patient questionnaires. All
patients were requested to complete these questionnaires

at baseline and every four weeks thereafter. In addition,
patient satisfaction with participation in the trial was assessed using the 4-item Was It Worth It (WIWI) questionnaire. The WIWI questionnaire was completed at 4 weeks
and at disease progression, at time of patient withdrawal
or study discontinuation, or 12 months from randomization, whichever occurred first. This questionnaire includes
a few key questions to determine patient perception of a
treatment being worth the trouble.

Statistical Analyses
All AEs and their severity were tabulated and summarized.
For the safety analyses, all patients who received at least
one dose of study drug were included; patients were analyzed according to the treatment that they received. Overall
AE rates for grade ≥3 events were compared between
the treatment groups using Chi-Square or Fisher’s Exact
tests.18,19
For phase II, the primary endpoint was to evaluate the
difference in efficacy between bevacizumab alone and
bevacizumab in combination with TRC105 as determined
by PFS. A sample size of 86 (43 per group) resulted in
90% power to detect at least a 3-month increase in median PFS. PFS was defined as time from randomization
to disease progression, with death being documented
as tumor progression. Patients who did not die or progress were censored at time of last tumor assessment.
PFS was estimated using the Kaplan-Meier method.20
The patient groups were compared using log-rank tests.
For efficacy analyses the intent-to-treat (ITT) population
was used, defined as all eligible patients belonging to
the treatment group to which they were randomized and
regardless of receiving study treatment. A sensitivity
analysis was included that used a modified ITT population, including only patients who had been registered
and randomized, and who had received at ≥1 study treatment cycle without a major violation.
Secondary endpoints included 6-month PFS, overall survival (OS, defined as time from start of therapy to death by
any cause with the distribution estimated using KaplanMeier), time to treatment failure (TTF, defined as the time
from study registration until documentation of progression,
unacceptable toxicity or refusal to continue study participation), and quality of life in both treatment arms. The modified ITT population was also used for the CEC analyses.
Data collection and statistical analyses were conducted
by the Alliance Statistics and Data Management Center.
Data quality was ensured by review of data by the Alliance
Statistics and Data Management Center and by the study
chairperson following Alliance policies. The study was
monitored at least twice annually by the Alliance Data and
Safety Monitoring Board.

Results
Patients and Baseline Demographics
In total, 15 patients were enrolled for the phase I part of the
trial (Figure 1A). One patient withdrew from the trial prior
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Target lesions were evaluated, and response was defined as complete response (CR) when there was a complete disappearance of all enhancing measurable and
nonmeasurable disease that was sustained for ≥4 weeks
and no new lesions had appeared. Partial response (PR)
was defined as a ≥50% decrease compared with baseline
in perpendicular diameters of all measurable enhancing
lesions, which was sustained for ≥4 weeks, without
new lesions or progression of nonmeasurable disease.
Progressive disease (PD) was defined as a ≥25% increase
in perpendicular diameters of enhancing lesions, compared with the smallest tumor measurement at baseline
or at best response, occurrence of any new lesion, clear
clinical deterioration, or failure to return for evaluation
due to death or deterioration, or clear progression of
nonmeasurable disease. Patients not qualifying for CR,
PR, or PD who were clinically stable were deemed to have
SD. All patients continued treatment until disease progression unless unacceptable toxicity occurred.

Galanis et al. TRC105 plus bevacizumab versus bevacizumab in GBM

Phase I
TRC105 + Bevacizumab
n = 15

1 Withdrawal of consent
prior to start of
treatment

TRC105 dose level 0
(6 mg/kg)
n=4

TRC105 dose level 1
(8 mg/kg)
n=3

TRC105 dose level 2
(10 mg/kg)
n=7

1 Patient replaced*
4 Evaluable for DLTs

0 Patients replaced
3 Evaluable for DLTs

1 Patient replaced†
n = 3 in cohort 1/2 each
6 Evaluable for DLTs

B

Phase II
n = 101

TRC105 + Bevacizumab
n = 52

Bevacizumab alone
n = 49

3 Withdrawal of consent prior to start
of treatment
1 Disease progression
1 Major violation

5 Withdrawal of consent prior to start
of treatment
1 Other

Reasons for treatment
discontinuation:
5 Refused further treatment
7 Adverse events
32 Disease progression
1 Other medical problem
1 Died on study
1 Other

Reasons for treatment
discontinuation:
5 Refused further treatment
5 Adverse events
31 Disease progression
1 Alternate treatment
1 Other

Evaluable for primary endpoint
n = 52

Evaluable for primary endpoint
n = 49

Figure 1. CONSORT diagrams for the A) phase I and B) phase II parts of the study. *Replaced for maximum tolerated dose analysis due to disease
progression prior to receiving TRC105. †Replaced for maximum tolerated dose analysis, the patient refused further treatment from cycle 1 day 11
onwards and withdrew consent.
  

to receiving study treatment. Four patients started on dose
level 0 (6 mg/kg weekly), 3 on dose level 1 (8 mg/kg), and
7 on dose level 2 (10 mg/kg) with, respectively, 4, 3 and 6
patients evaluable for DLTs. All patients in the phase I part
of the study discontinued treatment. Reasons for treatment discontinuation were disease progression (n = 11),
refusal of further treatment (n = 2), and AEs (n = 1). For
the phase II part of the study, 101 patients were included
and 52 were randomized to TRC105 with bevacizumab and
49 to bevacizumab alone (Figure 1B). Eight patients withdrew consent prior to beginning study treatment and were

excluded from the primary analysis per ITT. At time of
data analysis, all patients had discontinued treatment. The
most common reasons for treatment discontinuation were
disease progression (n = 63), AEs (n = 12), and refusal of
further treatment (n = 10). Reasons for treatment discontinuation were not significantly different between the treatment arms (P = .75).
Patient demographics and baseline characteristics for
both phase I and II of the study are summarized in Table 1.
When comparing the phase II arms, there was a difference
in the extent of resection at recurrence at any time, with
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Table 1. Patient Demographics and Baseline Characteristics
Characteristic

TRC105 + bev

Phase I

Phase II

Bev alone
Phase II

n = 15

n = 52

n = 49

53.0 (44.0–65.0)

58.5 (31.0–86.0)

56.0 (32.0–75.0)

Gender, n (%)
Female
Male
Years since end RT, median (range)

4 (26.7)

17 (32.7)

12 (24.5)

11 (73.3)

35 (67.3)

37 (75.5)

0.67 (0.08–2.17)

0.67 (0.17–10.17)

0.75 (0.17–3.50)

ECOG Performance Status
0

4 (26.7)

11 (21.2)

10 (20.8)

1

7 (46.7)

29 (55.8)

28 (58.3)

2

4 (26.7)

12 (23.1)

10 (20.8)

Missing

0

0

1

Numberof priorchemo regimens, n (%)
0

1 (6.7)

8 (15.4)

6 (12.5)

1

5 (33.3)

35 (67.3)

34 (70.8)

2

9 (60.0)

9 (17.3)

8 (16.7)

Missing

0

0

1

Corticosteroid use at entry, n (%)
Yes

6 (40.0)

27 (51.9)

27 (56.2)

No

9 (60.0)

25 (48.1)

21 (43.8)

Missing

0

0

1

Extent of resection (primary), n (%)
Biopsy

3 (20.0)

8 (15.4)

Subtotal resection

4 (26.7)

18 (34.6)

16 (33.3)

Gross total resection

8 (53.3)

26 (50.0)

28 (58.3)

Missing

0

0

4 (8.3)

1

Extent of resection (recurrence), n (%)
None

5 (33.3)

30 (58.8)

Biopsy

1 (6.7)

4 (7.8)

Subtotal resection

3 (20.0)

4 (7.8)

Gross total resection

6 (40.0)

13 (25.5)

Missing

0

1

28 (59.6)
0
12 (25.5)
7 (14.9)
2

Bev, bevacizumab; ECOG, Eastern Cooperative Oncology Group; RT, radiation therapy

  
more patients having gross total resection in the TRC105
plus bevacizumab arm and more patients having subtotal
resection in bevacizumab alone arm (P = .02).

MTD Determination
In phase I, the most frequently occurring AEs regardless
of relation to treatment were headache (n = 12), anemia
(n = 7), epistaxis (n = 7), hypertension (n = 6), thromboembolic event (n = 3), and hyperglycemia (n = 2). One DLT occurred in the dose level 2 cohort: during cycle 1 one patient
experienced grade 3 headache and hypertension. At cycle
2 the headache was resolved to grade 0 and the hypertension to grade 2. All other AEs in the trial were grade 1 or
2. The MTD was determined to be TRC105 10 mg/kg in combination with bevacizumab 10 mg/kg every 2 weeks.

Phase II Safety Data
AE data were available for 92 evaluable patients from phase
II: 49 patients treated with TRC105 plus bevacizumab and
43 with bevacizumab monotherapy. The most common
treatment-related AEs (TRAEs) that occurred in phase II are
summarized in Table 2. The incidence of AEs regardless of attribution was compared between the two treatment arms.
Significantly higher occurrences of anemia (P < .001), fatigue (P = .045), infusion-related reaction (P = .028), headache
(P = .037), and epistaxis (P < .001) were observed in the combination arm compared with the bevacizumab monotherapy
arm. There was also a general increase in the occurrence of
any grade ≥3 events in the combination arm (P < .001); this
difference was mainly driven by the incidence of grade ≥3
hematologic AEs (P < .001). There was no significant difference between the treatment groups for grade 4 AEs.
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Age, years, median (range)

TRC105 + bev

0
0
4 (9.3%)
7 (8.9%)
White blood cell decreased

Pharmacokinetics
TRC105 concentrations were determined during cycle
2, before and after treatment. Before treatment on cycle
2 day 1, the mean corrected concentration of TRC105 was
46.6 (± standard deviation of 37.4) µg/mL, which increased
to 208.8 (± 25.3) µg/mL post-treatment. At day 8 of cycle
2, the TRC105 concentrations were 51.5 (± 30.6) µg/mL
and 259.2 (± 94.6) µg/mL pre- and post-treatment, respectively, which fall within active therapeutic windows exceeding the target TRC105 concentration of 20 µg/mL both
at peak and trough.

Circulating Endothelial Cells

  

0
1 (2.3%)
Infusion-related reaction

10 (20.4%)

1 (2.0%)

1 (2.3%)

0
0

5 (10.2%)

0

2 (4.7%)

8 (18.6%)

15 (30.6%)
Epistaxis

Proteinuria

1 (2.3%)

0
4 (8.2%)

9 (18.4%)

1 (2.0%)

2 (4.7%)

9 (20.9%)

17 (34.7%)
Headache

Platelet count decreased

3 (7.0%)
16 (37.2%)
Hypertension

9 (18.4%)

3 (6.1%)

0

1 (2.3%)
2 (4.1%)

14 (28.6%)
6 (14.0%)

11 (25.6%)

31 (63.3%)

24 (49.0%)

Anemia

Fatigue

(N = 49)

Bev

(N = 43)

Bev + TRC105

(N = 49)

n = 92

Bev + TRC105
Bev

n = 92

Adverse event, n (%)

Grade ≥3
All grade

At the time of analysis, 13 patients were alive and remained
progression-free; the median time of follow-up for these patients was 37.2 months (95% CI: 22.9–NA). The 6-month PFS
rate was 0.25 (95% CI: 0.15–0.41) and 0.3 (95% CI: 0.19–0.48)
for the TRC105 plus bevacizumab and bevacizumab arms,
respectively. The median PFS for TRC105 plus bevacizumab
was 2.9 (95% CI: 2.76–4.86) months, and for bevacizumab
alone was 3.2 (95% CI: 2.60–4.63) months (Figure 2A).
Median OS was 9.7 (95% CI: 6.74–11.53) months for TRC105
plus bevacizumab and 7.4 (95% CI: 6.54–12.71) months for
bevacizumab alone (Figure 2B). The median TTF was 2.8
(95% CI: 2.14–3.22) and 2.6 (95% CI: 1.81–4.3) months for
TRC105 plus bevacizumab and bevacizumab alone, respectively (Figure 2C). There was no significant difference between the treatment arms in terms of PFS (P = .51), overall
survival (P = .81) or TTF (P = .57).
A sensitivity analysis of the survival data was undertaken, which included those patients who had received
≥1 cycle of treatment without a major treatment violation;
5 patients in the combination arm and 6 patients in the
bevacizumab monotherapy arm were excluded from this
analysis. Median PFS was 2.9 (95% CI: 2.76–4.86) months
for TRC105 plus bevacizumab, and 3.2 (95% CI: 2.60–4.63)
months for bevacizumab alone. Median overall survival for
the combination arm was 10.2 (95% CI: 6.80–11.66) and 7.4
(95% CI: 6.54–12.71) months for the bevacizumab arm, while
the median TTF was 2.8 (95% CI: 2.30–4.60) and 2.7 (95% CI:
2.04–4.53), respectively. In the sensitivity analysis, the differences between the treatment arms remained not significant
for PFS (P = .52), overall survival (P = .91), or TTF (P = .66).
The best response to treatment is summarized in Table 3.
For each of the treatment arms, 1 CR and 5 PRs were observed. SD was the best response for 33 patients treated
with TRC105 plus bevacizumab and 26 patients treated
with bevacizumab alone. Eight patients had PD after being
treated with TRC105 plus bevacizumab and 7 patients had
PD after treatment with bevacizumab alone. Overall, best
response was not significantly different between the treatment arms (13% versus 16%, P = .97).

Baseline data for CEC analysis was available from 89 patients; 47 patients in the TRC105 plus bevacizumab arm and
42 patients in the bevacizumab alone arm. At baseline, no
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Figure 2. Phase II efficacy endpoints. Kaplan-Meier curves for A) progression-free survival (PFS), B) overall survival (OS), and C) time to treatment
failure (TTF) in patients with GBM receiving either TRC105 with bevacizumab (bev) or bevacizumab alone.
  

significant differences were observed between the treat  
Table 3. Best Response Rates in the Phase II
Best response
rate (95%CI)

Phase II

Phase II

TRC105 + bev

Bev alone

n = 52

n = 49

Missing/not evaluable

5

10

CR

1/47

1/39

0.02 (0.00–0.11)

0.03 (0.00–0.13)

5/47

5/39

0.11 (0.04–0.23)

0.13 (0.04–0.27)

33/47

26/39

0.70 (0.55–0.83)

0.67 (0.50–0.81)

8/47

7/39

0.17 (0.08–0.31)

0.18 (0.08–0.34)

PR
SD
PD

numbers of CECs (≤27.86) were seen in 42% of patients and
39% of patients had no CD105+ CECs at baseline. The percentage of patients without CD105+ CECs at baseline was
slightly lower in the TRC105 plus bevacizumab arm (30%)
than in the bevacizumab alone arm (50%; P = .083). A lower
baseline CEC number was associated with a worse PFS
(hazard ratio [HR] = 1.75, P = .017). The treatment arm was an
effect modifier on this relationship. The numbers of CECs at
baseline were not significantly influential on PFS in patients
treated with TRC105 plus bevacizumab (HR = 1.27, P = .45),
but a significant influence of lower baseline CECs numbers
on PFS was seen for patients receiving bevacizumab alone
(HR = 2.55, p=0.007). When comparing treatment arms with
low or high baseline CECs, patients with low CECs receiving
bevacizumab alone had the shortest PFS (Figure 3A). A lower
percentage of CD31+CD105+ CECs at baseline was also significantly associated with shorter PFS (HR = 1.80, P = .017; Figure
3B). Increases in the numbers of CECs with a fold change ≥2.5
(HR = 1.83, P = .014; Figure 3C) during treatment were associated with worse PFS.

Bev, bevacizumab; CI, confidence interval; CR, complete response;
PD, progressive disease; PR, partial response; SD, stable disease.

  

ment groups in numbers of total or CD105+ CECs or percentages of CD31+CD105+ CECs (Supplementary Table 1). Low

Quality of Life
In total, 45 patients in the TRC105 plus bevacizumab arm
and 41 in the bevacizumab alone arm completed the
EORTC-QLQ-BN20 questionnaire at baseline. Of these, 33
patients in the TRC105 plus bevacizumab arm and 32 in the
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Figure 3. Circulating endothelial cells. Kaplan-Meier curves for progression-free survival (PFS) by A) treatment arm and low or high numbers of circulating
endothelial cells (CECs) at baseline, B) low or high percentages of CD31+CD105+ CECs at baseline, C) fold change in CEC numbers from baseline to cycle 2 (approximately 1 month).
  

bevacizumab alone arm had also completed questionnaires
at cycle 2. Supplementary Table 2 shows an overview of the
changes from baseline to cycle 2. A decrease in “future uncertainty” scores was reported by patients in both treatment arms (median –8.33 for both groups). Median scores
for other topics did not change from baseline to cycle 2, and
no significant difference was observed between the treatment arms. The overall quality of life median scores from
the EORTC-QLQ-C15-PAL also did not significantly change
from baseline to cycle 2 (Supplementary Table 3) for either
arm, and results did not significantly differ between treatment arms. From available WIWI questionnaires, 26 patients (72.2%) receiving TRC105 plus bevacizumab and 23
patients (71.9%) receiving bevacizumab indicated it was
worth being a part of the study.

Discussion
TRC105 in combination with bevacizumab was generally
well tolerated in patients with GBM. Only one DLT occurred
in the phase I part of the study, which was grade ≥3 headache and hypertension. As a result, the highest TRC105
dose tested in phase I, 10 mg/kg weekly in combination
with bevacizumab 10 mg/kg on day 1 of each 2 week cycle,
was established as the MTD and used for phase II of the
study. Interestingly, results from the phase I portion of this
study suggested it is feasible to enroll patients refractory

to bevacizumab, a challenging population that is often excluded from participation in clinical trials.
In the phase II portion of the study, several AEs were
more prominent in the TRC105 plus bevacizumab arm
compared with bevacizumab alone, specifically anemia,
fatigue, infusion-related reaction, headache, and epistaxis. These AEs have previously been associated with
TRC105 in trials with patients with prostate cancer21 and
hepatocellular carcinoma.22 The data presented within
also indicate that treating patients with both TRC105 and
bevacizumab appears to increase the severity of AEs,
mainly the proportion of patients suffering with grade 3
AEs, compared with bevacizumab alone. This is in contrast to published data in patients with renal cell cancer
where the combination of TRC105 plus bevacizumab did
not increase the overall frequency of grade ≥3 AE compared with bevacizumab monotherapy.23 Similarly, a
phase I trial in patients with solid tumors found no difference in the frequency or severity of AEs in patients who
received TRC105 plus bevacizumab, compared with the
safety profiles for each individual therapy (except from
headache).14 The differences observed in this trial may
be a result of the indication in which the combination is
being studied and the possible increased susceptibility
of this specific patient population to certain side effects
such as headaches. It is of note that despite the increased
frequency of AEs in the combination arm, this did not
translate in differences in quality of life as assessed by
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In conclusion, TRC105 in combination with
bevacizumab did not improve PFS compared to
bevacizumab alone in patients with recurrent GBM.
The combination of these 2 treatments has shown
promising results in at least one trial for a different
tumor type, as has TRC105 combined with other VEGF
inhibitors. Although the development of TRC105 may
be valuable for the development of future anti-cancer
therapies, GBM does not appear to be an optimal indication for this strategy. Further studies are necessary to determine optimal bevacizumab combinations
and alternative anti-angiogenic strategies for GBM
treatment.

Supplementary material
Supplemental material is available at Neuro-Oncology
Advances online.
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the EORTC-QLQ-BN20 and EORTC-QLQ-C15-PAL questionnaires or the WIWI questionnaire. Furthermore, >70%
of patients in both arms deemed that the participation in
this trial was worth it.
The combination of TRC105 plus bevacizumab did
not improve efficacy compared with bevacizumab
alone. The median PFS, OS and TTF were similar in
both treatment groups. The combination of TRC105
plus bevacizumab has previously shown activity in
patients with solid tumors. In one study, 45% (n=14)
of patients had a decrease in overall tumor burden;
of these, 10 patients had previously progressed after
a VEGF-targeted therapy. 14 Similar to our data, a trial
in patients with metastatic renal cell cancer also
demonstrated that the combination of TRC105 plus
bevacizumab did not improve patient outcomes; a
lower PFS (2.8 months) with the combination therapy
versus bevacizumab alone (4.6 months) was observed.
The patients in that study were highly refractory however and could have progressed after several other
VEGF-targeted agents prior to inclusion in the trial. 23
While CD105 was previously seen to be upregulated
after VEGF inhibition in mouse models, 11 a study
evaluating bevacizumab with TRC105 in patients with
renal cell cancer found contrary results and observed
a decrease in serum levels of CD105 after treatment
with bevacizumab. 23 It is possible that angiogenic factors other than CD105 are more prominent in patients
with GBM after VEGF-targeted therapy, which could
explain the lack of response seen in our trial.
Preliminary correlative analyses indicated that the duration of PFS may be influenced by numbers of CECs and
percentages of CD31+CD105+ CECs at baseline. Lower
levels of baseline CECs were associated with a worse PFS
in patients treated with bevacizumab alone. In addition, patients without CECs at baseline who developed these cells
during treatment with bevacizumab also had a lower PFS.
However, these results need to be considered with caution
as the number of patients who could be included in these
analyses was limited and the results are considered exploratory and hypothesis-generating in nature. Nevertheless,
this potential relationship between CECs and PFS in patients with GBM treated with bevacizumab is intriguing
and warrants additional investigation.
GBM is a fatal malignancy, commonly refractory to all
treatment options. Although our trial failed to demonstrate efficacy of the TRC105/bevacizumab combination
in GBM, trials examining the combination of TRC105 with
other VEGF targeting strategies did demonstrate promising results in other solid tumors. When TRC105 was
administered in combination with sorafenib in patients
with hepatocellular carcinoma, a response rate of 25%
was observed with a duration of response ranging from
4.4–27.6 months. The majority of the confirmed PRs (4/5)
were seen with a dose of 15 mg/kg TRC105 every 2 weeks
and no responses were seen at doses <10 mg/kg [19].
Axitinib in combination with TRC105 also demonstrated
preliminary activity in patients with metastatic renal cell
carcinoma with 29% of patients having PR, and a median
PFS of 11.3 months. This was a higher response rate and
longer PFS than expected with axitinib alone. All 5 responders in this study had previously been unresponsive
to sunitinib or pazopanib.24
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